the treatment of human bone marrow or human peripheral blood mononuclear cells ( pbmc ) with march 1e11 and either pooled human serum or autologous serum as a complement source resulted in cytolysis of greater than 99 % of okt3-positive lymphocytes .
C0229671
serum
C0009498
complement